Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STOCKWATCH: J&J points to medtech dip, Novartis lobs MS grenade to Teva

This article was originally published in Scrip

Executive Summary

Second-quarter earnings season kicked off properly this week with the world's largest healthcare company, Johnson & Johnson, reporting (scripintelligence.com, 16 July 2013). The healthcare conglomerate commonly known as J&J has a market capitalisation of nearly $260bn and is so diverse that it provides a window into other pure-play pharmaceutical, consumer, medical device and diagnostic companies, as well as a number of specific drugs, the revenues on which, much smaller companies are dependent.

You may also be interested in...



Stockwatch: Earnings Season Appears Not At Home To Brexit

On the morning of the vote by the UK to leave the EU, I speculated firstly that the ensuing currency swings would come too late to impact the imminent second-quarter pharma earnings announcements but secondly, that they could have an effect on the guidance of companies for the rest of the year. In the opening week of earnings season I am currently one for two in the prediction stakes as the effects of Brexit barely figured in either the results or the full-year guidance.

Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season

Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.

Stockwatch: New Year, New Politics; Same Old Pricing And Generic Challenges

A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel